Get the Stockscreener App
44.39
1.42%
-0.59
Kiniksa Pharmaceuticals International Plc stock is traded at $44.39, with a volume of 118.39K.
It is down -1.42% in the last 24 hours and up +7.83% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$44.98
Open:
$45
24h Volume:
118.39K
Relative Volume:
0.26
Market Cap:
$3.36B
Revenue:
$597.97M
Net Income/Loss:
$35.92M
P/E Ratio:
99.02
EPS:
0.4483
Net Cash Flow:
$101.73M
1W Performance:
+4.13%
1M Performance:
+7.83%
6M Performance:
+35.27%
1Y Performance:
+129.98%
1-Day Range:
$43.50
$45.50
1-Week Range:
$42.00
$45.50
52-Week Range:
$18.25
$45.50
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
44.38 | 3.41B | 597.97M | 35.92M | 101.73M | 0.4483 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.35 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.26 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.93 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.36 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Mark Ragosa Sells 17,845 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Essex Investment Management Co. LLC - MarketBeat
Y Intercept Hong Kong Ltd Has $248,000 Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 830 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 2,602 Shares - MarketBeat
Barry Quart Sells 12,528 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis: 23% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighHere's What Happened - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 51,204 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup - Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighTime to Buy? - MarketBeat
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator - Seeking Alpha
Kiniksa Pharmaceuticals International, Plc's (NASDAQ:KNSA) Revenues Are Not Doing Enough For Some Investors - 富途资讯
Risk Off: Can Kiniksa Pharmaceuticals Ltd reach all time highs this yearQuarterly Profit Summary & Consistent Income Trade Ideas - baoquankhu1.vn
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN
Campbell & CO Investment Adviser LLC Makes New $1.48 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
First Week of March 20th Options Trading For Kiniksa Pharmaceuticals International (KNSA) - Nasdaq
Kiniksa Pharmaceuticals International PLC (KNSA) Trading Down 4. - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Is Down 6.7% After Raising 2026 ARCALYST Revenue OutlookHas The Bull Case Changed? - simplywall.st
Kiniksa Pharmaceuticals appoints new chief operating and strategy officers By Investing.com - Investing.com South Africa
Kiniksa Pharmaceuticals appoints new chief operating and strategy officers - Investing.com
Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO - TipRanks
Kiniksa Pharmaceuticals International, plc Appoints Management Team, Effective January 10, 2026 - marketscreener.com
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - Defense World
Wedbush Raises Price Target for Kiniksa Pharmaceuticals (KNSA) | - GuruFocus
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next - TechStock²
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 5.6%Time to Sell? - MarketBeat
High Growth US Tech Stocks To Watch In January 2026 - simplywall.st
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Dow - GuruFocus
Kiniksa reports 62% growth in ARCALYST revenue, forecasts 2026 sales By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals Provides Corporate Update - TradingView — Track All Markets
Kiniksa reports 62% growth in ARCALYST revenue, forecasts 2026 sales - Investing.com
Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - Defense World
Kiniksa Pharmaceuticals International, plc $KNSA Stock Holdings Reduced by Peregrine Capital Management LLC - MarketBeat
Insider Sell: Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmac - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells $502,680.00 in Stock - MarketBeat
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Down 6.2%Here's What Happened - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Voya Investment Management LLC - Defense World
Rice Hall James & Associates LLC Reduces Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) - Finviz
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Time to Buy? - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week HighTime to Buy? - MarketBeat
Barry Quart Sells 20,129 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - Defense World
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
8.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):